# Antifibrotic Activity Of GI262570 In Chronic Hepatitis C Subjects

> **NCT00244751** · PHASE2 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 265 (actual)

## Conditions studied

- Cirrhosis, Liver

## Interventions

- **DRUG:** GI262570 0.5 mg
- **DRUG:** GI262570 1.0 mg
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00244751
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-11-02
- **Primary completion:** 2008-03-13
- **Final completion:** 2008-03-13
- **Target enrollment:** 265 (ACTUAL)
- **Last updated:** 2017-12-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00244751

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00244751, "Antifibrotic Activity Of GI262570 In Chronic Hepatitis C Subjects". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00244751. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*